Working on muscle- or cardiac-targeted gene therapy research? Have a program that could benefit from a next-generation AAV capsid? Solid’s proprietary capsid, AAV-SLB101, has demonstrated robust muscle transduction and reduced liver exposure in animal models and initial data from the INSPIRE DUCHENNE Phase 1/2 clinical trial. Reach out to our team at businessdevelopment@solidbio.com to discuss: · MTA access available for academic researchers · Bespoke licensing open for biotech and pharma partners Learn more: solidbio.com/partners #SolidInside #SolidStartsHere #SolidEngineered #NextGeneration #GeneTherapy #AAV #Capsid